Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation (MNKD) specializes in innovative inhaled therapies for diabetes and respiratory diseases, notably through its FDA-approved Afrezza® inhaled insulin. This page aggregates official announcements, clinical trial updates, and strategic partnership news critical for understanding the company's trajectory.
Investors and researchers will find curated press releases covering financial results, regulatory milestones, and technology licensing agreements. The collection emphasizes developments in MannKind's core platforms: the Technosphere® drug delivery system and iSPERSE™ formulation technology.
Content includes updates on pulmonary arterial hypertension treatments, diabetes management solutions, and global expansion initiatives. All materials maintain factual accuracy without speculative analysis, adhering to financial disclosure standards.
Bookmark this page for streamlined access to MNKD's latest business developments and scientific advancements. Verify time-sensitive details directly through company filings or official communications.
MannKind Corporation (NASDAQ:MNKD) has successfully achieved the final development milestone under its collaboration with United Therapeutics for their dry powder formulation of treprostinil, a treatment for pulmonary arterial hypertension (PAH). All clinical trials are fully enrolled, including the BREEZE study and pivotal pharmacokinetics study. MannKind's stability program has met the requirements for a regulatory filing, paving the way for an FDA submission in early 2021. With all milestone payments received, MannKind will also earn royalties and manufacturing margins from TreT sales.
MannKind Corporation (NASDAQ:MNKD) reported third quarter 2020 results showing a net revenue of $15.4 million, comprising $7.3 million from Afrezza, an increase of 27% year-over-year. The company achieved a gross profit of $3.7 million, a significant recovery from a loss of $0.7 million in the same quarter of 2019. Cash and cash equivalents stood at $52.4 million as of September 30, 2020. The net loss for the quarter was $11.3 million or $0.05 per share, slightly higher than $10.4 million in Q3 2019. The company is on track to finalize Treprostinil Technosphere development by year-end.
MannKind Corporation (NASDAQ:MNKD) will announce its 2020 third quarter financial results on November 4, 2020, at 5:00 PM ET. CEO Michael Castagna and CFO Steven Binder will discuss the results and corporate updates during a conference call. Interested parties can listen live via the company's website or join a telephone replay available for 14 days post-call. MannKind specializes in inhaled therapeutic products, notably the FDA-approved Afrezza® inhalation powder, the only inhaled ultra-rapid acting mealtime insulin available in the U.S. and Brazil.
MannKind Corporation (Nasdaq: MNKD) announced its participation in several upcoming conferences where CEO Michael Castagna will speak. Key events include the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 3:30 pm EDT, the Cantor Global Virtual Healthcare Conference on September 15 at 8:40 am EDT, and the Oppenheimer Fall Healthcare Summit on September 21 at 10:50 am EDT. The presentations will be accessible through a live webcast on the company's website, with replays available for 14 days.
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will present at the BTIG Virtual Biotechnology Conference on August 11, 2020, at 2:00 pm ET. The live webcast will be accessible via the company's website, with a replay available for 14 days after the event. MannKind focuses on inhaled therapeutic products for diabetes and orphan lung diseases, with its flagship product, Afrezza® (inhaled insulin), being the only FDA-approved inhaled ultra-rapid-acting mealtime insulin available in the U.S.
MannKind Corporation (NASDAQ:MNKD) reported 2Q 2020 Afrezza net revenue of $7.0 million, up 15% from 2Q 2019, contributing to a total revenue of $15.1 million. For 1H 2020, net revenue was $15.0 million, a 35% increase year-over-year. Gross profit surged 90% to $3.3 million, boosting gross margin from 29% to 47%. The company reported a net loss of $10.3 million, an improvement from $12.4 million in 2Q 2019. Cash reserves stood at $63.2 million. New Chief Commercial Officer Alejandro Galindo joined to enhance growth.
MannKind Corporation (NASDAQ: MNKD) will announce its 2020 second quarter financial results and provide corporate updates during a conference call scheduled for August 5, 2020, at 5:00 PM ET. The call will feature CEO Michael Castagna and CFO Steven Binder. Interested parties can access the live call via the company's website, with a playback option available for 14 days post-call.
MannKind is focused on developing inhaled therapies for diabetes and orphan lung diseases, highlighting its commercial product, Afrezza®.
MannKind Corporation (NASDAQ: MNKD) has announced its participation in the Lytham Partners Virtual Investor Growth Conference, scheduled for June 24, 2020, at 12 pm ET (9 am PT). CEO Michael Castagna will present during a virtual fireside chat. A webcast of the presentation will be available on MannKind's investor website. Additionally, management will engage in one-on-one meetings with institutional investors on the same day. MannKind is known for developing inhaled therapeutic products, including the FDA-approved Afrezza®, an inhaled insulin product.
MannKind Corporation (Nasdaq: MNKD) announced the presentation of new clinical data for Afrezza® (insulin human) Inhalation Powder at the American Diabetes Association’s 80th Scientific Sessions on June 13, 2020. The study, led by Dr. Mark Kipnes, highlighted a significant 0.8% reduction in A1C levels in patients switching from injected insulin to Afrezza over 14 weeks. Participants reported improved diabetes quality of life and maintained glucose levels within the target range. Afrezza is the only inhaled ultra-rapid-acting mealtime insulin available in the U.S.
MannKind Corporation (NASDAQ:MNKD) reported a strong first quarter of 2020 with net revenue of $8.0 million from Afrezza, marking a 58% increase from Q1 2019. Gross profit rose significantly to 48%, up from 21% in the previous year. Total revenues reached $16.2 million, but collaboration revenue declined by $4.2 million due to the end of a research agreement. The net loss narrowed to $9.3 million, or $0.04 per share, reflecting reduced operating expenses. Cash reserves decreased to $39.2 million amid $11.2 million in operating cash use.